GAUMOND MEDICAL GROUP INC. (GMG) is a dynamic and innovative Canadian company specialized in biomedical engineering. GMG is dedicated to the research and development of transportable hyperbaric technologies and works in the field of composite materials.  GMG develops only medical grade products that are intended to provide hyperbaric oxygen therapy (HBOT) treatments up to 3 ATA (2 bar, 30 psig).

Since its creation, GMG has distinguished itself by its willingness to break new ground in the design of ever more efficient monoplace hyperbaric devices. The use of composite materials of high performance is one of the peculiarities of GMG.

Over the years, GMG has become a pioneer in the field of monoplace flexible hyperbaric chambers.



Our company is committed to the improve quality of life. The mission of GMG is to democratize  hyperbaric oxygen therapy (HBOT) through the development and promotion of innovative, safe and affordable technologies. HBOT is a therapy that improves the quality of life and health of people suffering from pathologies recognized by the Undersea and Hyperbaric Medical Society (UHMS). In some cases HBOT is an auxiliary therapy, while in others it is the only known therapy. However, HBOT is still commonly unknown from the public mainly due to the expensive cost of equipment required for its application. By providing a flexible and transportable monoplace chamber for both emergency and chronic treatments, GMG now offers a new alternative for natural and effective HBOT treatments.



Our hyperbaric chamber HematoCare™ distinguishes itself from competition by a competitive price and high mobility. Only the use of light and high-tech composite materials in a innovative design can offers such competitive advantages.

The HematoCare™ is now CE marked and obtained all required European approvals to meet the demand ot recognized intended uses for chronic and emergency HBOT treatments. U.S. and Canadian approvals are in process.